Terns Pharmaceuticals, Inc.
TERN
Classificação em ações
#3572
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Preço da ação
$52.95
Última sincronização: 2026-05-15
Valor de mercado
$4.77B
Variação (1 dia)
0.00%
Variação (1 ano)
529.61%
País
US
Negociar Terns Pharmaceuticals, Inc. (TERN)
Categoria
Healthcare
Lucros da Terns Pharmaceuticals, Inc. (TERN)
Lucros em Dec 2025 TTM: $-95.63M
De acordo com os últimos relatórios financeiros da Terns Pharmaceuticals, Inc., os ganhos atuais da empresa são de $-95.63M. Em 2023, a empresa teve ganhos de $-89.97M, uma diminuição em relação a aos ganhos de 2022, que foram de $-59.99M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Terns Pharmaceuticals, Inc. de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-95.63M | 7.94% |
| 2024 | $-88.59M | -1.53% |
| 2023 | $-89.97M | 49.98% |
| 2022 | $-59.99M | 20.82% |
| 2021 | $-49.65M | 70.87% |
| 2020 | $-29.06M | -57.79% |
| 2019 | $-68.84M | 280.64% |
| 2018 | $-18.09M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -5,616.18% |
US
|
|
| $-3.09B | 3,128.20% |
US
|
|
| $-4.02B | 4,099.90% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,139.87% |
NL
|
